Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $14.00 price target on Nyxoah SA (NASDAQ:NYXH), currently trading at $7.42, following the company’s receipt of FDA PMA approval for its Genio system. According to InvestingPro data, the stock appears undervalued based on its Fair Value analysis, with analyst targets ranging from $11.93 to $14.59.
The approval covers patients with moderate-severe Obstructive Sleep Apnea (OSA) who have an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. This regulatory milestone follows positive results from Nyxoah’s DREAM trial, which demonstrated a 71% median AHI reduction. The company maintains a healthy financial position with a current ratio of 3.59 and more cash than debt on its balance sheet.
The Genio system showed efficacy regardless of sleeping position, including a 66.6% median reduction in supine sleepers, which Nyxoah considers a key clinical advantage for patients who spend approximately 35-40% of the night in this position.
Nyxoah has already established a full U.S. commercial organization in preparation for the FDA approval, with 75 physicians already trained on the Genio technology. Importantly, the Genio System is not contra-indicated for patients with Complete Concentric Collapse ( CCC (WA:CCCP)).
The company’s hypoglossal nerve stimulation (HGNS) offering enters what Cantor Fitzgerald describes as a "one-player market," addressing an annual $10 billion U.S. market opportunity. While the company reported revenue of $4.72M in the last twelve months, InvestingPro analysis indicates strong sales growth potential ahead. Get deeper insights into Nyxoah’s market position and growth prospects with InvestingPro’s comprehensive research report, available along with 8 additional ProTips.
In other recent news, Nyxoah SA reported its first-quarter financial results for 2025, revealing revenues of $1.1 million. This figure was below both Cantor Fitzgerald’s projection of $2.4 million and the FactSet consensus estimate of $1.6 million. The reported revenue also marked a year-over-year decline of about 15%, primarily due to performance in Germany, where the company generated nearly all of its revenue. Meanwhile, Cantor Fitzgerald maintained an Overweight rating on Nyxoah with a price target of $14.00, following these financial disclosures. Additionally, Stifel kept its Buy rating on Nyxoah with a price target of $12.00 after the publication of the DREAM study in the Journal of Clinical Sleep Medicine. The study presented findings related to Nyxoah’s Genio device, used for treating obstructive sleep apnea. These developments highlight the ongoing interest and analysis from investment firms regarding Nyxoah’s market performance and product advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.